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Increasing evidence highlighted the role of cancer stem cells (CSCs) in the development
of tumor resistance to therapy, particularly in glioblastoma (GBM). Therefore, the
development of new therapies, specifically directed against GBM CSCs, constitutes
an important research avenue. Considering the extended range of cancer-related
pathways modulated by histone acetylation/deacetylation processes, we studied
the anti-proliferative and pro-apoptotic efficacy of givinostat (GVS), a pan-histone
deacetylase inhibitor, on cell cultures enriched in CSCs, isolated from nine human GBMs.
We report that GVS induced a significant reduction of viability and self-renewal ability in
all GBM CSC cultures; conversely, GVS exposure did not cause a significant cytotoxic
activity toward differentiated GBM cells and normal mesenchymal human stem cells.
Analyzing the cellular and molecular mechanisms involved, we demonstrated that GVS
affected CSC viability through the activation of programmed cell death pathways. In
particular, a marked stimulation of macroautophagy was observed after GVS treatment.
To understand the functional link between GVS treatment and autophagy activation,
different genetic and pharmacological interfering strategies were used. We show that
the up-regulation of the autophagy process, obtained by deprivation of growth factors,
induced a reduction of CSC sensitivity to GVS, while the pharmacological inhibition of
the autophagy pathway and the silencing of the key autophagy gene ATG7, increased
the cell death rate induced by GVS. Altogether these findings suggest that autophagy
represents a pro-survival mechanism activated by GBM CSCs to counteract the efficacy
of the anti-proliferative activity of GVS. In conclusion, we demonstrate that GVS is a novel
pharmacological tool able to target GBM CSC viability and its efficacy can be enhanced
by autophagy inhibitory strategies.
Keywords: glioblastoma multiforme, programmed cell death, histone deacetylase inhibitor, cancer stem cell,
autophagy
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INTRODUCTION
Glioblastoma (GBM) is fatal, highly invasive brain tumor still
displaying poor prognosis (Ohgaki and Kleihues, 2013) even
after aggressive multi-modal therapy, including neurosurgery,
radiotherapy, and chemotherapy with temozolomide (Stupp
et al., 2005). Different GBM features are responsible for the
therapeutic failure: the peculiar structure of the brain and
the invasive behavior of GBM prevent complete surgical
tumor excision; the brain blood barrier prevents systemically
administered chemotherapeutics to reach the central nervous
system (CNS) in clinically effective concentrations (Omuro
and Deangelis, 2013), the molecular complexity of GBM
showing a variety of genetic alterations, strongly influencing the
therapy outcome, since different mutations might determine
different drug sensitivity (Brennan et al., 2013; Patel et al.,
2014). In addition, the presence of cancer stem cells (CSCs)
within the tumor mass is responsible for the recurrence
after therapy (Vescovi et al., 2006; Florio and Barbieri,
2012). CSC theory proposes that tumor development is
dependent on a small cell population endowed with self-
renewal and multilineage differentiation ability, a strong
resistance to conventional chemotherapy, and the ability to
propagate the tumor when xenografted in animal models
(Wurth et al., 2014). Since the most aggressive or refractory
cancers contain the highest number of CSCs, the therapeutic
importance of the eradication of this particular cancer cell
subpopulation is a relevant research goal to overcome
GBM therapy resistance (Al-Hajj et al., 2004; Singh et al.,
2004).
The wide variety of genetic alterations in GBMnecessitates the
use of strategies targeting processes like chromatin remodeling,
which can revert the altered status of multiple genes. The
wide range of cellular and molecular effects mediated by
histone deacetylase inhibitors (HDACi) make these drugs
suitable candidates for the treatment of such heterogeneous
tumors (Lee et al., 2015). HDACi act through the inhibition
of histone deacetylases, enzymes that control chromatin
remodeling and acetylation of histone and non-histone
proteins (Ververis and Karagiannis, 2012). Pharmacologically-
induced unbalanced acetylation (histone acetyl transferase
activity) and deacetylation (HDAC activity) in favor of the
former, creates an hyperacetylated status, promotes a relaxed
chromatin structure and an accessible DNA backbone for the
transcriptional machinery favoring the activation/repression of
gene transcription (Peart et al., 2005), by which HDACi induce
cell death (Bolden et al., 2013), cell cycle arrest, senescence
(Pazolli et al., 2012), differentiation, or autophagy (Robert et al.,
2011) in tumor cells. In GBM cells, HDACi reduce proliferation
via cell cycle arrest and apoptosis, suppress tumor growth
in experimental in vivo models, and potentiate the effects of
radiotherapy, cytotoxic agents and immune-therapeutics (Thurn
et al., 2011). Several HDACi, including SAHA, trichostatin A,
valproic acid, belinostat, have been tested in GBM models, and
several clinical trials, based on HDACi monotherapy or as drug
association strategies are concluded or ongoing (De Souza and
Chatterji, 2015).
We report the efficacy of givinostat (GVS), a pan-histone
deacetylase inhibitor, on human GBM CSC viability and self-
renewal and the involvement of apoptosis and macroautophagy
(hereafter referred as autophagy) in this response.
MATERIALS AND METHODS
Tumor Samples, Cell Cultures, and
Chemicals
Nine glioma post-surgical specimens were obtained from the
Neurosurgery Department of the IRCCS-AOU San Martino IST,
(Genova, Italy) after patients’ informed consent and Institutional
Ethical Committee approval. All patients underwent surgery
for the first time and never received chemo- or radio-therapy.
Tumors were derived from 6 males and 3 females and the
mean age was 57.5 years. Pathological analysis classified gliomas
as grade IV glioblastoma (n = 8), or grade III anaplastic
astrocytoma (n = 1) according to World Health Organization
criteria. Cell cultures deriving for each tumor sample were coded
as GBM1 to GBM9. Patients and tumors details are reported in
Supplementary Table 1.
All GBM-derived CSCs were previously isolated and
characterized (Gatti et al., 2013; Wurth et al., 2013). Tumor
samples were immediately processed to obtain cell cultures
enriched in CSCs. Briefly, cell suspension obtained after
mechanical dissociation, was filtered through a 40µm strainer
(BD Biosciences, San Jose, CA, USA) to remove aggregates,
and cultivated in serum-free medium containing DMEM-
F12/Neurobasal (1:1), B27 supplement (Gibco-Thermofisher,
Paysley, UK), 2 mM L-glutamine (Lonza, Basel, Switzerland),
1% penicillin-streptomycin (Lonza), 15µg/ml insulin (Sigma-
Aldrich, St.Louis, MO, USA), 2µg/ml heparin (Sigma-Aldrich)
and completed with recombinant human bFGF (10 ng/ml;
Miltenyi Biotec, Cologne, Germany) and EGF (20 ng/ml;
Miltenyi Biotec) (Bajetto et al., 2013). This medium is defined
as “complete medium.” These cells gave rise to floating tumor-
spheres after 2 weeks, but can also growing as stem cells
in monolayer, after spheres disaggregation and in presence
of Matrigel (BD Biosciences, San Jose, CA, USA), without
losing expression of stem cell markers, spherogenic properties,
differentiation and tumorigenic potential (Griffero et al., 2009).
All the cell cultures analyzed in this study were previously
characterized for tumor-initiating capacity by orthotopic
xenograft, induced by injection of 10,000 sphere-derived
cells in 6–8-weeks old non-obese diabetic severe combined
immunodeficient (NOD/SCID) mice (Charles River
Laboratories, Wilminglon, MA, USA), as detailed in previous
studies (Carra et al., 2013; Gritti et al., 2014; Corsaro et al., 2016).
Animals were housed in pathogenic-free conditions, and handled
in agreement with the institutional and national guidelines for
the care and use of laboratory animals (Italian D.lgs 26/2014);
the experimental plan was approved by the IRCCS AOU S.
Martino-IST (Genova, Italy) Institutional Animal Care and Use
Committee (IACUC).
To induce differentiation, GBM CSC cultures were seeded
and maintained for 2 weeks in DMEM/F12 supplemented
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with 2 mM L-glutamine, penicillin-streptomycin and 10% FBS
(Euroclone, Milano, Italy). Deprivation of growth factors was
induced removing bFGF, EGF, and the B27 supplement from the
culture medium.
Three humanGBMestablished cell lines were also used: T98G,
U373-MG, and U138-MG (ATCC). GBM cell lines were grown
in DMEM supplemented with 2 mM L-glutamine, penicillin-
streptomycin and 10% FBS.
Human umbilical cords (n= 2) were collected from full-term
women, immediately after cesarean section at the Gynecology
Department of International Evangelical Hospital (Genova,
Italy), after informed consent and approval by Institutional
Ethic Committee. After vessel removal, cords were digested with
collagenase I-S (0.5µg/ml, Sigma-Aldrich) for 1 h to expose
Wharton-Jelly and isolated cells cultured in DMEM (10% FBS,
2 mM L-Glutamine). MSCs were used after full characterization
by flow cytometry (MSC Phenotyping Kit, Miltenyi Biotec), as
defined by International Society for Cellular Therapy (Dominici
et al., 2006).
The pan-HDAC inhibitor givinostat (ITF2357) was kindly
provided by Italfarmaco S.p.A. (Cinisello Balsamo, Italy).
Givinostat was dissolved in DMSO at the stock concentration
of 10 mM and for all experiments it was diluted in the specific
medium to obtain the final concentrations. Rapamycin (Cell
Signaling Technology, Danvers, MA, USA) and bafilomycin-
A1 (Sigma-Aldrich), were used to promote the induction and
inhibition of autophagy, respectively. Both were dissolved in
DMSO at the stock concentration of 100µM, and for all
experiments drugs were diluted in the specific medium to
obtain the appropriate concentration. Controls received the same
amount of residual DMSO (not exceeding 0.1%) than treated
samples.
Sphere-Formation Assay
GBM CSCs were seeded in complete medium without Matrigel,
in 48-well plates at 1000 cells/well. After 24 h cells were exposed
to increasing concentration of GVS (0.1–2µM), and sphere-
formation capacity was monitored after 7 days, to allow spheres
generation. The number of spheres in wells was quantified using
a digital camera mounted on a transmitted light microscope
and visually calculated by three independent operators. To
further demonstrate the inhibitory activity of GVS on sphere-
formation process, GBM-derived tumor-spheres, generated in
the absence or presence of GVS (0.1–0.5µM), were disaggregated
and re-plated in fresh medium avoid of GVS. Spheres-formation
efficiency (SFE) (Wurth et al., 2016), calculated as the number of
formed spheres/1000 plated cells, was re-evaluated after 7 days.
MTT and Trypan-Blue Dye Exclusion
Assays
Mitochondrial activity, as index of cell viability, was evaluated
by measuring the reduction of 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich,). GBM
CSCs were plated into 96 or 48-well plates (pre-coated with
Matrigel), and the number of cells/well (ranging from 1000 to
5000) was adjusted depending on different proliferation rates
and time of treatment. At the end of each treatment, cells were
incubated with MTT solution (2.5 mg/ml), for 2 h. After MTT
removal, the formed purple formazan crystals were dissolved
in DMSO, and absorbance measured at 570 nm wavelength
(Pattarozzi et al., 2008).
Trypan blue exclusion assay was used to evaluate cell viability
reduction induced by GVS treatment. Initially, 5000 cells/well
were seeded in 24-well plates, pre-coated with Matrigel. After
24 h, cells were treated with increasing concentration of GVS for
additionally 48, 72, and 96 h. Every 24 h, viable cells were counted
in the presence of Trypan blue 0.4% w/v (Bio-Rad, Marnesla-
Coquette, France), to distinguish between dead and live cells,
using the TC-20 R© automated cell counter (Bio-Rad) (Villa et al.,
2016).
Drug Synergism Evaluation
To determine potential synergistic drug effects on growth of
CSCs GBM1, GBM2, and GBM3, cells were exposed to various
combinations of GVS (0.5µM) and bafilomycin-A1 (1.25–50
nM). Cell viability was determined by MTT assay after 48
and 72 h of treatment. Drug interactions (synergistic, additive,
antagonistic) were determined by the median effect analysis
method, as described (Chou and Talalay, 1984; Chou, 2010),
using the CompuSyn software (ComboSyn Inc., Paramus, NJ,
USA). This approach takes into account the potency, the shape,
and the slope of the dose-dependent neutralization curve of each
drug alone and in combination, to calculate a combination index
(CI). A CI value of 1 indicates an additive effect, <1 indicates
synergism, and >1 indicates antagonism.
Annexin V/PI Double Staining
GBM CSCs were treated with GVS and bafilomycin-A1 alone or
in association for 48 or 72 h, depending on the experiments. After
the treatment, cells were washed gently with PBS, trypsinized,
pelleted, secondly washed in PBS and finally counted. According
to Annexin V-FITC Apoptosis detection Kit (eBioscience,
Hatfield, UK), cells were resuspended in the Annexin Binding
Buffer at the concentration of 2–5 × 105 cells/ml, then 5µl
of Annexin-V was added to 195µL of the cell suspension and
incubated for 15 min, at the room temperature and protected
from direct light. Propidium Iodide (20µg/ml) was added and
cells were analyzed by flow cytometry (FACSCanto II flow
cytometer, BD Biosciences) recording 10,000 events per sample.
Annexin V-positive cells were considered in the early stages
of apoptosis, whereas cells in the late stages of apoptosis were
Annexin V- and PI-positive (Carra et al., 2013).
Real-Time PCR Expression Analysis
Total RNA from GBM CSCs was extracted using the Aurum
Total RNA Mini Kit (Bio-Rad), according to the manufacturer’s
instruction, and reverse transcribed into cDNA using the iScript
cDNA Synthesis Kit (Bio-Rad). Single stranded cDNA products
were analyzed by Real-time PCR using the SsoFastTM Eva
Green Supermix (Bio-Rad,) on a CFX96 Touch Real-time
PCR (Bio-Rad). Cycling conditions were set at 94◦C for 30 s,
60◦C for 30 s and 72◦C for 30 s, for 37 cycles. Primers, for
MAP1LC3B amplification, were pre-designed by PrimePCR (Bio-
Rad). Human HPRT1 and TBP pre-designed primers (Bio-Rad)
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were used as internal controls. Levels of target genes in each
sample were normalized on the basis of HPRT1 and TBP
amplification and reported as relative values (Mathur, 2014).
Immunoblotting Analysis
Following specific treatments, cells were lysed in buffer
containing 1% Igepal, 20 mM Tris–HCl, pH 8, 137 mM NaCl,
10% glycerol, 2 mMEDTA, 1mMphenylmethylsulfonyl fluoride,
1 mM sodium orthovanadate, 10 mM NaF (all from Sigma-
Aldrich), and the “Cømplete protease inhibitor mixture” (Roche)
for 20 min at 4◦C. Nuclei were removed through centrifugation
(5000 rpm at 4◦C for 10 min); total protein concentration
was measured with Bradford assay (Bio-Rad). Proteins (40–
60µg) were resuspended in Laemmli buffer (2% SDS, 62.5
mM Tris, pH 6.8, 0.01% bromophenol blue, 1.43 mM β2-
mercaptoethanol,and 0.1% glycerol) and were separated on 10 or
12% (depending on protein size) SDS-PAGE, and subsequently
transferred onto PVDFmembrane (Bio-Rad) (Massa et al., 2004).
The following antibodies were used: anti-LC3B, anti-Beclin1,
anti-Atg7, and anti-acetyl-α-tubulin (Lys40) (all from Cell
Signaling Technologies). β-actin (Cell Signaling Technologies)
and α-tubulin (Sigma Aldrich) were used as internal control to
ensure equal loading and transfer of proteins. Antibodies were
all diluted at 1:1000 in 3% bovine serum albumin (BSA), except
α-tubulin which was diluted 1:7500 in Tween 20 (0.1%)/PBS.
Species-specific peroxidase-linked ECL secondary antibodies
(GEHealthcare USA, 1:5000 dilutions) were used. Protein signals
and densitometric analysis were performed using the Clarity
Western ECL substrate (BioRad) and the Chemi-Doc System
(Bio-Rad).
LC3B-GFP Autophagosome and Electron
Microscopy Analysis
For autophagosome detection, GBM CSCs were seeded at the
density of 5000 cells/well in 48-well plates pre-coated with
Matrigel. After 12 h, cells were transduced with BacMam
LC3B-GFP viral particles (multiplicity of infection, MOI =
30), according to the Premo Autophagy Sensor Kit (Invitrogen,
Carlsbad, CA, USA). After 16 h of incubation, cells were treated
with GVS (0.5µM), bafilomycin-A1 (10 nM, added 4 h before
the end of the time interval), the combination of the two
drugs, or vehicle (controls); LC3B-GFP signals were monitored
after additional 24 h, using an inverted fluorescence microscope
(40X magnification, Eclipse Nikon TS100, Minato, Japan). GFP-
positive vesicles were analyzed in number and shape (area) using
the Autocounter tool as described (Fassina et al., 2012).
For ultrastructural analysis, GBM CSCs were grown at 75%
confluence, and treated with GVS (0.5µM) or vehicle. Samples
were prepared according to Marchesi et al. (2014). Specifically,
after 48 h p.t, cells were harvested by centrifugation at 800
rpm for 3 min and fixed with 2% glutaraldehyde in medium,
maintained for 2 h at room temperature. Cells were then rinsed in
PBS (pH 7.2) overnight and post-fixed in 1% aqueous OsO4 for 2
h at room temperature. Cells were pre-embedded in 2% agarose
in water, dehydrated in acetone, and finally embedded in epoxy
resin (Electron Microscopy Sciences, EM-bed812). Ultrathin
sections (50–60 nm) were collected on formvar-carbon-coated
nickel grids and stained with uranyl acetate and lead citrate. The
specimens were finally observed with a Zeiss EM900 electron
microscope equipped with a 30 µm objective aperture and
operating at 80 kV.
Cell Transfection and Atg7 Silencing
To modulate Atg7 protein expression, GBM2 CSCs (80%
confluence) were transiently transfected with Lipofectamine
LTX reagent (Invitrogen) in presence of pooled Silencer select
validated siATG7 sequences (s20650, s20651; Ambion, USA) at
the final concentration of 150 nM or with the mock solution
alone, as negative control. To perform the viability assay (MTT),
cells were plated in 96-well plates (2000 cells/well) and assayed
after 24, 48, and 72 h p.t. For protein lysates, transfection was
performed on cells seeded on 60 mm petri dishes with the same
concentration of pooled siATG7 sequences.
Statistical Analysis
All reported experiments were carried out in triplicate and
performed at least three times. Data were reported as means ±
SEM. All statistical analysis (ANOVA followed by Dunnett’s post-
hoc test, or unpaired two-tailed Student’s t-test), were calculated
with Graph-Pad Prism 5.0. p ≤ 0.05 was considered statistically
significant.
RESULTS
GVS Affects the Viability of GBM Cell Lines
and CSC Enriched Cultures
Different established humanGBM cell lines (i.e., U87-MG, U138-
MG, and T98G) were initially tested to evaluate the effect of GVS
on cell viability, using the MTT assay. Time-course (from 24
to 96 h) and dose-response (GVS 0.1–2µM) experiments were
performed. GVS reduced cell viability in a concentration- and
time-dependent manner (Supplementary Figure 1), although no
effects were observed for short time treatments (24 h) or GVS
concentrations lower than 0.25µM.
Due to the higher translational potential of GBM CSCs
compared to cell lines (Lee et al., 2006), we confirmed the effect
of GVS on the viability of CSC-enriched cultures isolated from
nine human GBMs. GVS induced anti-proliferative effects in all
CSC cultures grown as monolayers in a concentration- and time-
dependent manner, with, also in this case, lower efficacy observed
for shorter treatments (Figure 1, Supplementary Table 2). The
mean GVS IC50, calculated after 72 h of treatment, was 0.85 µM
but this value decreased proportionally with GVS exposure time,
confirming the time-dependent activity of the drug (Table 1).
Growing CSCs as monolayer on Matrigel allows for better
cellular and biochemical characterization without interfering
with stem-like characteristics (Griffero et al., 2009; Wurth et al.,
2013), although the ability to grow as tumor-spheres is a defining
feature of these cells. Thus, we verified whether this experimental
condition interfere with CSC drug responsivity. Comparing GVS
(0.1–2µM) effects on CSCs grown as either tumor-spheres or
monolayer, we observed no differences in drug sensitivity (data
not shown).
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FIGURE 1 | GVS dose-response curves (0.1–2.0µM) in nine adherent GBM cell cultures enriched in CSCs. Cell viability was determined by MTT assay after
24–144 h of treatment. Experiments were performed in triplicate and percentage of inhibition was calculated vs. untreated control cells.
The cellular and molecular mechanisms of GVS activity on
GBM CSCs were analyzed in the most responsive CSC cultures
(GBM1, GBM2, and/or GBM3) (Table 1), in comparison, in
selected experiments, with less responsive cultures (GBM7,
GBM8, GBM9). To evaluate the contribution of cytostatic
or cytotoxic effects of GVS, GBM1, and GBM2 CSCs were
assayed by Trypan blue exclusion test, after treatment with
GVS (0.5–2 µM for 48–96 h). Forty-eight hour treatment
caused cytostatic effect at all concentrations tested (with the
exception of GBM1 treated with high GVS concentration)
with no changes in the number of dead cells compared to
untreated cells at T0. However, extending treatment time, cells
started to die in a concentration- and time-dependent manner
(Supplementary Figure 2).
To establish the minimum time of GVS exposure required
to decrease CSC viability, we performed cell growth recovery
experiments (Favoni et al., 2010). GBM1, GBM2, and GBM3
cultures treated with 0.5µMGVS, were washed and incubated in
drug-free fresh medium. Cell viability by MTT assay determined
either immediately after medium replacement or after additional
24–72 h (see Supplementary Figure 3 for the experimental
scheme). Twenty-four hour treatment decreased growth rate and
the low proliferative activity partly persisted during the following
24 h, but after additional recovery time the cells reacquired an
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TABLE 1 | IC50 value (microM) of GBM CSCs exposed for different time
intervals to GVS.
CSCs 72h 96h 120h 144h
GBM1 0.63 0.35 0.15 0.11
GBM2 0.55 0.33 0.24 0.19
GBM3 0.56 0.20 0.09 0.09
GBM4 0.51 0.49 – –
GBM5 Not reached 0.28 0.32 0.19
GBM6 1.47 0.93 0.93 0.66
GBM7 1.19 1.54 0.20 0.09
GBM8 1.23 1.01 0.89 0.57
GBM9 1.29 0.83 0.72 0.37
MEAN IC50 0.85 0.66 0.44 0.30
VALUE (RANGE) (0.51–1.47) (0.20–1.54) (0.09–0.93) (0.09–0.66)
Calculations were performed using GraphPad Prism software. (Not reached, absence of
a significant GVS activity; empty boxes, not performed).
exponential-like growth rate, reaching levels comparable to non-
treated cells. The extension of the treatment with GVS to 48 or
72 h delayed the time to recovery causing, after 72 h of treatment,
a significant reduction in cell viability (Supplementary Figure 4).
GVS Inhibition of Cell Survival Is Specific
for CSCs and Is Diminished after
Differentiation
GVS anti-proliferative effect was also tested in differentiated
GBM cells obtained by shifting CSC cultures from growth
factor-enriched to FBS-containing medium. After 14 days,
differentiated GBM CSCs lose in vivo tumorigenicity and stem
cell marker expression and exhibit glial and/or neuronal marker
expression (Gritti et al., 2014; Banelli et al., 2015). GVS did
not affect the viability of differentiated GBM1 and GBM2
cells (hereafter named GBM1 DIFF and GBM2 DIFF), even
after 144 h of treatment with the highest concentration of
drug (Supplementary Figure 5A). Furthermore, GVS treatment
of two cultures of normal human umbilical cord-derived
mesenchymal stem cells (MSCs) caused no reduction of viability
at all concentrations and times tested in MSC1, whereas only
the highest GVS concentration (2µM) slightly reduced MSC2
viability (Supplementary Figure 5B). These results confirm that
independently from the culturing conditions, the antitumoral
effects of GVS are selectively directed against CSC specific
proliferation mechanisms, with GBM DIFF cells and MSCs
mostly insensitive to the drug.
Self-renewal is a defining feature of both normal and cancer
stem cells. Tumor-sphere formation is considered an indirect
index of self-renewal of CSCs (Soeda et al., 2008). To understand
whether GVS affects GBM CSC self-renewal, we performed a
spherogenesis assay. GBM1, GBM3, GBM5, GBM7, and GBM9
CSCs were plated at 1000 cells/well in the presence of increasing
concentrations of GVS and allowing to generate spheres for 7
days. As reported in Figure 2A (and quantified in Figure 2B),
GVS inhibited spherogenesis in a dose-dependent manner. At
low GVS concentrations, tumor-spheres were less compact and
organized, while a clear reduction of number and size of spheres
was observed on increasing the drug concentration. At the
highest concentrations tested (GVS 1 and 2µM), the inhibition of
cell viability in all the cultures was predominant and masked the
drug effect on spherogenesis, making difficult the interpretation
of the results. A statistically significant reduction of the number
of spheres was seen in GBM1, GBM3, and GBM9 starting from
the GVS concentration of 0.25–0.5µM which had low effect on
CSC viability, suggesting that GVS inhibition of sphere formation
is independent from anti-proliferative effects. An additional
experimental approach was performed using GBM1, GBM2, and
GBM3 preformed tumor-spheres, which were treated with low
GVS concentrations (0.1–0.5µM) for 7 days, disaggregated and
re-plated in GVS-free medium (Figure 3A,B). While untreated
CSCs regenerate spheroids, pre-treatment with GVS dose-
dependently abolished their spherogenesis ability.
Effects of GVS on Apoptosis/Autophagy
Processes in GBM CSCs
GVS was tested for the ability to interfere with apoptosis and
autophagy processes. GBM1, GBM2, and GBM3 CSCs, treated
with GVS (up to 2µM) for 72 h, were tested in AnnexinV-
PI double staining by FACS analysis (Figure 4), showing a
concentration-dependent increase of cells entering the early
phases of apoptosis (approximately 30% for GBM1 and GBM3,
and 50% for GBM2).
To study GVS modulation of autophagy, as a preliminary
evaluation we analyzed the relative expression of MAP1LC3B,
coding for LC3B, in GVS-treated GBM1, GBM2, and
GBM3 CSCs by Real-time PCR. GVS treatment induced a
transient increase in MAP1LC3B mRNA content (detectable
after 24 and 48 h, and back to the baseline after 72 h,
Supplementary Figure 6). Then, the effect of GVS on LC3-
II and Beclin1 protein content was investigated in GBM1,
GBM2, GBM3, GBM6, GBM7, and GBM9 cells. CSCs were
treated for 72 h with GVS (0.5–2µM) or with the autophagy
inducer rapamycin (50 nM, for 72 h): LC3-II and Beclin1 showed
an increased amount following GVS treatment, often higher
than those caused by rapamycin administration (Figure 5).
Increased acetyl-α-tubulin content, a direct marker of HDAC6
inhibition (Haggarty et al., 2003), was observed following GVS
administration, confirming the efficacy of the drug on its specific
target (Figure 5).
To verify whether GVS-mediated increase in LC3-II and
Beclin1 was the resultant of autophagy activation, GBM1,
GBM2, and GBM3 CSCs were transduced with a baculovirus
LC3B-GFP expressing vector. Cells were treated with GVS
(0.5 µM), bafilomycin-A1 (10 nM) or with the combination
of the two drugs and analyzed for the amount of GFP-
positive vesicles, using the Autocounter tool as described
(Fassina et al., 2012). GVS, bafilomycin-A1 and the combined
treatment induced significant increases of fluorescent vesicles
in the investigated cells; furthermore, the additive results in
increasing GFP puncta in the combined GVS+bafilomycin-A1,
compared to bafilomycin-A1 alone administration, suggested
a direct increase of the autophagy flux induced by GVS
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FIGURE 2 | GVS effect on GBM CSC sphere formation. (A) GBM1, GBM3, GBM5, GBM7, and GBM9 were maintained in the selective medium for stem cells in
the absence or presence of increasing concentrations of GVS. Sphere formation was visually monitored and after 14 days the number of spheres/well was counted.
Representative microphotographs (magnification 10X) are reported. (B) Histogram reports the mean sphere number from four experiments (*p < 0.05, **p < 0.01,
***p < 0.001, ANOVA followed by Dunnett’s post-hoc test).
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FIGURE 3 | GVS effect on GBM CSCs on self-renewal measured as secondary sphere formation. (A) GBM1, GBM2, and GBM3 were grown in stem cell
permissive conditions for 7 days to allow sphere appearance (P = Primary spheres) in the presence or absence of increasing concentration of GVS. Spheres were
then disaggregated and single cells were replated in medium without GVS and, following further 7 days, the formation of secondary spheres (S) was evaluated.
Microphotographs (magnification 10X) are representative of GVS inhibitory effect on spherogenesis. (B) Histograms indicate the sphere-formation efficiency (SFE) of
secondary spheres (mean number of spheres/number of cells seeded per well) for each condition against untreated controls. Control value was set at 1 (*p < 0.05
and **p < 0.01 using ANOVA followed by Dunnett’s post-hoc test).
(Figures 6A,B). Transmission electron microscope analysis of
GVS-treated cells, revealed a high number of double membrane
autophagic-like vesicles containing partially undigested material.
Features of mitophagy (the presence of mitochondria within
autophagosomes), multivesicular bodies and phagophores (a site
of autophagosome formation) were also scored (Figure 6C).
Functional Role of Autophagy in
GVS-Treated GBM CSCs
The functional significance of the autophagy induced by (or in
response to) GVS treatment was assessed using different known
autophagy inhibitors/inducers (Klionsky et al., 2016).
To arrest the autophagy process, GBM1, GBM2, and GBM3
CSCs were pre-treated with bafilomycin-A1 (up to 50 nM) for
2 h before being incubated with GVS (0.5µM). Cell viability
was evaluated by MTT assay. Forty-eight hours of combined
treatment with bafilomycin-A1 and GVS induced a significant
decrease in cell viability, compared to bafilomycin-A1 or GVS
alone (the combination of bafilomycin-A1+GVS reduced GBM1
viability of 57% compared to−25% of bafilomycin-A1 and−23%
GVS; in GBM2 the combined treatment caused a reduction of
−74%, in comparison to bafilomycin-A1 −31% and GVS −20%;
while in GBM3 we observed −46% viability after bafilomycin-
A1+GVS, compared to−8% of bafilomycin-A1 and−20%GVS),
with a further increase in the cytotoxic effect induced by the
combined treatment after 72 h (Figure 7A). To determine the
statistical significance of the GVS/bafilomycin-A1 association,
the combination index (CI) values were calculated and plotted
using the CompuSyn software (Supplementary Figure 7): CI
values above 1 are indicative of antagonism, while below 1 of
synergism. GBM1, GBM2, and GBM3 showed CI values <1
starting from the combination GVS 0.5 µM/bafilomycin-A1 2.5
nM for GBM1 (range, 0.2–0.6 at 48 h; 0.07–0.6 at 72 h), GVS 0.5
µM/bafilomycin-A1 5 nM for GBM2 (range, 0.3–0.9 at 48 h, 0.3–
0.9 at 72 h) and GVS 0.5 µM/bafilomycin-A1 2.5 nM for GBM3
(range: 0.4–0.6 at 48 h; 0.02–0.4 at 72 h), confirming a synergistic
effect exerted by GVS in association with the autophagy inhibitor
bafilomycin-A1. Similar results were obtained when the effects of
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FIGURE 4 | In vitro assessment of apoptosis in GBM1, GBM2, and GBM3 CSCs. FACS analysis of Annexin V-PI staining was used to observe the induction of
apoptosis and/or necrosis by GVS. Histograms represent the percentage of each cell population (early apoptotic, late apoptotic and necrotic) after 72 h of GVS
treatment (0.25, 0.5, 1.0, and 2.0µM). Statistical analysis was performed using ANOVA followed by Dunnett’s post-hoc test (*p < 0.05, **p < 0.01).
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FIGURE 5 | Modulation of autophagic marker expression following GVS administration in GBM1, GBM2, GBM3, GBM6, GBM7, and GBM9 CSCs. (A)
LC3-I, LC3-II, Beclin1 and acetyl-α-tubulin protein levels was determined by immunoblotting. β-actin was used as protein loading control. Lysates were obtained from
cells treated for 72 h with GVS (0.5, 1.0, and 2.0µM) or rapamycin (50 nM). (B) Densitometric analysis of protein expression. Values were normalized to β-actin
expression and reported as percentage of untreated controls. Experiments were performed in triplicate, data represent mean ± SEM, (*p <0.05; **p <0.01, ***p <
0.001, ANOVA followed by Dunnett’s post-hoc test).
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FIGURE 6 | LC3B-GFP expression in GBM CSCs exposed to GVS. (A) Cells were transduced with baculovirus LC3B-GFP expressing vector. GVS (0.5µM) was
added 16 h after transduction to allow LC3B-GFP expression. Bafilomycin-A1 (10 nM), alone or in combination with GVS (0.5µM), was added 4 h before the end of
the 24 h interval. LC3-GFP signals were monitored using an inverted fluorescence microscope (40X magnification). (B) Evaluation of numbers of LC3-GFP vesicles
was performed using Autocounter tool. GFP-positive vesicles were considered with area >1 mm2 in 50 cells for each treatment. Statistical analysis was performed
(Continued)
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FIGURE 6 | Continued
using ANOVA followed by Dunnett’s post-hoc test (*p < 0.05, **p < 0.01) comparing GVS, bafilomycin-A1, GVS+bafilomycin-A1 treatments to the respective
untreated (CTR) GBM CCSs. (C) Representative ultra-structures analysis using transmission electron microphotographs of GBM1 and GBM2 treated with GVS
(0.5µM) for 72 h. GBM1 and GBM2 cells (106) were grown at 75% confluence and treated (c–f) or not (a,b) with GVS. Cells were harvested, fixed and stained for
ultra-structural visualization. Specimens were then observed with a Zeiss EM900 electron microscope. Magnifications are 7000X (a–d) and 12000X (e,f). “A” indicates
large intracellular vesicles, likely autophagosomes; “M+A” indicates a mitochondrion fused with a vesicle (mitophagy), “MVB” indicates a multivesicular body, finally
“PHA” indicates a phagophore (isolation membrane) assembly site.
the combined GVS (0.5µM)/bafilomycin-A1 (5 nM) treatment
was investigated on the induction of apoptosis in GBM2 and
GBM3 CSCs. As compared to single drug treatments, the drug
combination increased the percentage of apoptotic cells (GBM2:
41.27% of early+late apoptotic cells with the association, vs. 19.84
and 6.25% for GVS and bafilomycin-A1, respectively; for GBM3,
16.4% of early+late apoptotic cells with the association, vs. 5.89
and 6.25% for GVS and bafilomycin-A1, respectively). Also the
percentage of PI-positive, necrotic cells was increased with the
combined treatment with GVS and bafilomycin-A1 (Figure 7B).
These results suggested that the inhibition of autophagy by
bafilomycin-A1 facilitated GVS-dependent apoptotic cell death
in GBM CSCs. Furthermore, GVS+bafilomycin-A1 treatment
produced an increase of LC3-II and p62 content, as compared
to the amount of these proteins following individual drugs
treatments. Conversely, in presence of the autophagy-activator
rapamycin or with GVS alone, p62 protein levels were reduced
as a result of the increase in autophagy-mediated protein
degradation (Figures 8A,B).
To better decipher the role of autophagy in GVS antitumor
activity, GBM2 CSCs were transfected with siATG7 validated
sequences, to arrest autophagy by reducing the intracellular
content of Atg7. The efficacy of gene silencing was verified
24 h post-transfection when Atg7 protein was significantly
down-regulated as compared to mock and not-transfected cells
(Figure 9, left panel). Treatment of siATG7-GBM2 with GVS
caused a further decrease of cell viability (Figure 9, right panel),
confirming that the arrest of autophagy enhances GVS tumor
cytotoxicity, as also showed by bafilomycin-A1 treatment.
Finally, a widely adopted culture-starvation scheme was
applied to activate autophagy in GBM1 and GBM2 CSCs. In
detail, CSCs were deprived of growth factors for 60 h before
being treated with GVS (up to 2 µM) and cell viability measured
by MTT assay. Deprivation of growth factors prevented GVS-
dependent cell death, and the activation of autophagy in these
conditions was demonstrated by increased LC3-II and reduction
in p62 protein levels (Supplementary Figure 8).
DISCUSSION
In this paper we report that in human GBM stem cells,
the inhibition of autophagy using both chemical and RNAi
approaches increases the antitumor efficacy of givinostat.
Givinostat (ITF2357, GVS) is a hydroxamic acid-derivative,
orally active, pan-HDACi. GVS has anti-inflammatory, anti-
neoplastic and anti-angiogenic properties (Leoni et al., 2005),
with pro-apoptotic effects in hepatocellular carcinoma (Armeanu
et al., 2005), non-small cells lung cancer (Del Bufalo et al., 2014)
and acute myeloid leukemia cells (Galimberti et al., 2010).
We report the efficacy of GVS in reducing viability of human
GBMCSCs, the subpopulation responsible for GBM resistance to
conventional therapy and patients’ fatal outcome (Bonavia et al.,
2011; Chen et al., 2012; Florio and Barbieri, 2012). In vitro, CSCs
retain genotypic and phenotypic features of the tumor they are
derived from, which are progressively lost when the cells are
grown in FBS-containing media, as occurs in established cell
lines (Lee et al., 2006). Thus, results obtained using CSC-enriched
cultures possess a higher traslational impact than those obtained
adopting established cell lines. CSC-enriched cultures, obtained
from nine human GBMs, were cultured both as spheroids and
monolayers retaining the stem-like biological and phenotypical
characteristics (expression of stem cell markers, multilineage
differentiation, self-renewal, and tumorigenicity in vivo; Griffero
et al., 2009; Wurth et al., 2013).
Firstly, we documented that GVS powerfully reduces viability
of all CSCs analyzed, independently from the genotypical and
phenotypical heterogeneity observed in the GBMs: we observed a
prolonged pharmacological activity that could be useful during in
vivo experimental schemes. GVS also inhibited CSC self-renewal,
a mechanism necessary to preserve CSCs within the tumor
microenvironment. It is important to highlight that the culture
conditions used to grow CSCs (non-adherent tumor-spheres or
monolayers in the presence of Matrigel) did not affect GVS
efficacy. In contrast, differentiatedGBM cells or normal stem cells
are modestly affected by GVS-induced cell death. Accordingly,
previous studies reported that GVS is cytotoxic for hepatoma cell
lines but not for normal human hepatocytes (Armeanu et al.,
2005), and, in agreement with our results, that MSCs are resistant
to GVS at concentrations higher than 1 µM for at least 72 h
(Golay et al., 2007). The reduced activity against non-tumor stem
cells while impairing CSC viability, renders GVS an interesting
candidate for further clinical evaluations. In addition, we report
that GVS had a lower effect on differentiated CSC, further
supporting the selectivity of GVS against CSC subpopulation.
It was reported that antitumor activity of GVS depends
on the activation of apoptotic pathways (Pathil et al., 2006;
Golay et al., 2007; Galimberti et al., 2010). We report that
the effect of GVS on GBM CSC viability is associated not
only with apoptotic cell death but also with the activation
of macroautophagy. Autophagy is a central cell degradation
system involved in several physiological and pathophysiological
events (Rabinowitz and White, 2010), including cancer (Mathew
et al., 2009; Macintosh and Ryan, 2013). A functional link
between HDACi and autophagy was demonstrated in cancer
cells (Zhang and Zhong, 2014). To this regard, we evaluated
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FIGURE 7 | Evaluation of the role of autophagy in GVS inhibitory effect on GBM CSCs. (A) GBM1, GBM2 and GBM3 CSCs were treated with GVS 0.5 µM
(black bars), bafilomycin-A1 1.25, 2.5, 5, 10, 25, and 50 nM (gray bars) or with the combination of all doses of the two drugs (pre-treatment with bafilomycin-A1 for 2
h; white bars) for 48 and 72 h. Cell viability was monitored by MTT assay. Statistical significance was calculated using ANOVA followed by Dunnett’s post-hoc test;
(*p < 0.05, **p < 0.01; ***p < 0.001, vs. control). (B) In vitro assessment of apoptosis in GBM2 and GBM3 cells treated with bafilomycin-A1 (5 nM) or GVS (0.5 µM),
alone or in combination. FACS analysis of Annexin V-PI staining was used to measure apoptosis/necrosis. Histograms represent the percentage of each cell population
after 48 h of drug exposure. Statistical analysis was performed using ANOVA followed by Dunnett’s post-hoc test (*p < 0.05, **p < 0.01, ***p < 0.0001 vs. control).
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FIGURE 8 | Effect of the combined treatment with GVS and bafilomycin-A1 on the LC3-II and p62 protein levels. (A) Representative immunoblots of LC3-II
and p62 protein levels. Cell lysates were obtained from GBM1, GBM2, and GBM3 CSCs treated with GVS (0.5–1.0 µM), bafilomycin-A1 (5 nM), rapamycin (40 nM),
and with GVS 0.5 µM/bafilomycin-A1 combination (2 h pre-treatment with bafilomycin-A1). α-tubulin content was used as loading control. (B) Densitometric analysis
of LC3-II and p62 protein levels. Data were normalized against α-tubulin and expressed as percentage of untreated control values. Statistical analysis was performed
using ANOVA followed by Dunnett’s post-hoc test (*p < 0.05, **p < 0.01;***p < 0.001 vs. control) comparing GVS, bafilomycin-A1, rapamycin, GVS+ bafilomycin-A1
treatments to the respective untreated (CTR) GBM CCSs.
the capability of GVS to modify the autophagy process in CSCs,
measuring the expression of main ATG proteins. In particular,
GVS treatment produced increasing amount of key autophagy
executory proteins LC3-II and Beclin1, clearly suggesting that
the drug administration induced marked differences within the
autophagy process. To further confirm this result, the effect of
GVS on autophagy was also assessed by autophagosome analysis.
Autophagosomes express LC3-II on the outer membranes,
while LC3-I isoform, originated by different post-translational
modifications, has a typical cytoplasmic diffuse expression
pattern. GVS treatment of GBM CSCs, previously transduced
with LC3-GFP baculovirus, induced a significant accumulation
of discrete fluorescent LC3-GFP puncta, likely representing
autophagosomes. Moreover, increased levels of LC3-GFP in
the presence of GVS or compounds interfering with the
autophagosome-lysosome fusion (i.e., bafilomycin-A1), was
indicative of an increase of the synthesis of autophagy-related
membranes (autophagy induction) rather than a reduction in
vesicle clearance as for autophagy blockage (Klionsky et al., 2016).
Moreover, transmission electron microscopy ultrastructural
evaluation highlighted a marked increase in autophagy-like
vesicles after GVS exposure. Altogether, these molecular and
cellular features indicate that GVS treatment induces the
activation of autophagy in GBM CSCs.
As widely discussed (Choi et al., 2013; Macintosh and Ryan,
2013; White, 2015), the contradictory role of autophagy in
cancer makes difficult to understand whether this mechanism
is per se beneficial or inhibitory for the malignant progression.
The possible dual functional role of autophagy, i.e., promoting
programmed cell death fate or conferring a pro-survival favorable
phenotype to the cancer cell, can determine the success or
failure of anti-cancer therapies (Palumbo and Comincini, 2013).
This opposite behavior represents an adaptive response of
the tumor cells to the therapy, and is associated to several
tumor-environmental conditions, such as specific or off-targets
effects of the drug used, tumor cell type and the state
of stem-like or differentiated cells (Galluzzi et al., 2015).
To decipher the contribution of the autophagy process to
the cytotoxic effects of GVS, autophagy in GBM CSCs was
positively or negatively modulated using different experimental
approaches. To obtain the autophagy inhibition: the down-
regulation of key genes and/or proteins and the blockade of
the autophagy flux preventing the fusion of autophagosomes
with lysosomes; to activate the autophagy process: rapamycin
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FIGURE 9 | Atg7 silencing effects on cell viability along with GVS in GBM CSCs. Equal amount of proteins obtained from GBM2 control (CTR), GBM2
transfected without siATG7 (MOCK) and GBM2 transfected with siATG7 were assayed. Immunoblotting analysis (left panels) was performed, 24 h post-transfection, in
order to ensure ATG7 silencing and Atg7 downregulation. β-actin was used as loading control. MTT cell viability assay (right panels) was performed at 24, 48, and 72
h after GVS administration (0.25, 0.5, and 1.0 µM), in CTR, MOCK and siATG7 transfected GBM2 cells. Statistical analysis was performed using ANOVA followed by
Dunnett’s post-hoc test (*p < 0.05, **p < 0.01; ***p < 0.001 vs. control).
treatment or growing cells in medium deprived of growth
factors.
Bafilomycin-A1, used to inhibit the autophagy flux, is a
specific inhibitor of the late phase of autophagy that prevents
the acidification of the autophagic vacuoles and inhibits the
fusion between autophagosomes and lysosomes (Yamamoto
et al., 1998). In parallel, the inhibition of autophagy was achieved
by down-regulating ATG7 gene by siRNA. Silencing ATG7, or
other key autophagy genes, provides an effective strategy to arrest
this pathway blocking the autophagosomes formation and the
degradation processes (Saiki et al., 2011; Criollo et al., 2012;
Klionsky et al., 2016). In this way, we show that the inhibition of
autophagy by both molecular and pharmacological approaches,
increases the anti-proliferative and pro-apoptotic effects of GVS
on GBM CSCs. This result was confirmed in cells in which
autophagy was activated by deprivation of growth factors. The
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FIGURE 10 | Schematic representation of the effect of GVS on GBM CSCs, differentiated GBM cells and MSCs. GVS reduced CSC viability through
apoptosis activation and self-renewal impairment; at the same time, GVS induced activation of the autophagy process that resulted in a partial protection of CSCs
from GVS pharmacological activity. The autophagy flux arrest, mediated by bafilomycin-A1 co-administration or by ATG7 silencing, enhanced the GVS pro-apoptotic
activity, therefore suggesting a pro-survival effect of the autophagic process to counteract the effect of GVS. Importantly, GVS did not reduce cells viability in
differentiated GBM cells and MSCs.
depletion of nutrients is one of the main stimuli triggering
autophagy (Mizushima and Klionsky, 2007). When the nutrients’
supply is limited, cells activate autophagy to generate a source
of metabolic substrates to sustain the energetic requirement for
survival (Kang and Avery, 2008). We report that deprivation
of growth factors in CSCs and the consequent activation of
autophagy results in a protective effect against GVS antitumor
activity.
Taken together, these findings suggest that the activation of
autophagy occurring during GVS treatment has a cytoprotective
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effect that, supporting CSC survival, reduces HDACi efficacy.
In other terms, tumor cells respond to GVS-induced cell death
with the activation of autophagy, a process directed to catabolize
damaged proteins and organelles. Lastly, our data indicate
that combined treatment with GVS followed by autophagy
inhibition has strikingly synergistic anti-tumor activity in GBM,
similarly to lung (Del Bufalo et al., 2014), hepatoma (Liu
et al., 2010; Yuan et al., 2014), breast (Rao et al., 2012) cancer
models. Consistent with these data, we propose a mechanistic
evaluation of the possible synergism between GVS effects and
autophagy inhibition that enhances the loss of GBMCSC viability
(Figure 10).
On the other hand, our results differ from previous studies
showing that the combined treatment with imipramine and
ticlopidine elicits cell-lethal autophagy in mouse models of
gliomagenesis (Shchors et al., 2015). However, it must be pointed
out that the quantitatively and qualitatively differentmodulations
of autophagy in our and in the previous study might result in
either pro-survival or cytotoxic effects (White et al., 2015).
In conclusion, we demonstrate that GVS is a promising
pharmacological agent; its inhibitory activity against CSC
proliferation and self-renewal, accomplished with high potency
and efficacy, allows us to consider GVS as a novel possible
adjuvant approach for GBM treatment. The identification of
GVS as a drug specifically directed against CSCs could represent
a significant pharmacological alternative for GBM patients.
Moreover, our results suggest that, in light of the cellular and
biological complexity of GBM, GVS therapeutic efficacy could
be intensified by the association with autophagy inhibitors,
since these compounds could synergize and revert the resistance
to therapeutic interventions of CSCs, and reduce the drug
concentration required to achieve a significant tumor mass
reduction.
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Supplementary Figure 1 | GVS dose-response curves (0.1–2 µM) on
U87-MG, U138-MG, and T98G cell viability. Every 24 h, cell viability was
determined by MTT assay for up to 96 h. Experiments were performed in triplicate
and the percentage of viability was calculated vs. untreated control cell. Statistical
analysis was performed with ANOVA test followed by Dunnett’s post-hoc test (∗p
< 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001).
Supplementary Figure 2 | Trypan blue exclusion assay on GBM1 and
GBM2 CSCs. Analysis was performed after GVS (0.5, 1, 2 µM) exposure from 48
to 72 h (black columns represent cells number at T0). Data represent the mean
and the SD of three independent replicates; (for dead cells: ∗p < 0.05, ∗∗p <
0.01, ∗∗∗p < 0.001, by ANOVA test followed by Dunnett’s post-hoc test).
Supplementary Figure 3 | Schematic representation of the experimental
plan of time-scale cell growth recovery test.
Supplementary Figure 4 | Cell growth recovery assay performed on GBM1,
GBM2, and GBM3 CSCs. Cells were treated with GVS (0.5 µM), for 24, 48, and
72 h. After each time of exposure, culture medium was replaced with a fresh one
devoid of GVS and cell viability was tested by MTT assay at T0 (time of medium
replacement), and after 24, 48, and 72 h. Histograms indicate the percentage of
cell survival compared to untreated control value at T0 (
∗p < 0.05; ∗∗p < 0.01,
∗∗∗p < 0.001, on ANOVA test followed by Dunnett’s post-hoc test).
Supplementary Figure 5 | GVS dose-response curves performed on (A)
differentiated GBM1 and GBM2 CSCs and (B) human umbilical
cord-derived MSCs. Cell viability was tested after 24–144 h of GVS treatment
(0.1–2 µM) and was determined by MTT assay. Experiments were performed in
triplicate and percentage of inhibition was calculated vs. untreated control.
Statistical analysis was performed with ANOVA test followed by Dunnett’s
post-hoc test (∗p < 0.05, ∗∗p < 0.01).
Supplementary Figure 6 | MAP1LC3B expression in GBM1, GBM2, and
GBM3 CSCs. Cells were treated with GVS (1 µM) for 24, 48, and 72 h and
assayed for MAP1LC3B mRNA levels by Real time qPCR. Results are given as
relative mRNA expression, in arbitrary units of the ratio of the target RNA over
HPRT1 and TBP expression levels. Statistical analysis was performed with ANOVA
test followed by Dunnett’s post-hoc test. Bars represent the mean of three
independent experiments ± SD (∗p < 0.05; ∗∗p < 0.01).
Supplementary Figure 7 | CompuSyn software evaluation of the
synergistic effect of GVS in combination with bafilomycin-A1 in GBM
CSCs. Isobolograms of drug combination on GBM1, GBM2, and GBM3 CSC
viability after treatment for 48 and 72 h, are represented. Combination index (CI) is
represented by symbols above (indicate antagonism between drugs) or below the
line (indicate synergy) and in the Table on the right.
Supplementary Figure 8 | Effect of deprivation of growth factors on GVS
activity in GBM CSCs. GBM1 and GBM2 CSCs were maintained in the absence
of growth factors for 60 h; after this period cells were treated with GVS (0.1, 0.25,
0.5, 1.0, and 2.0 µM) for further 48 h and viability was assessed by MTT assay. In
parallel the same study was performed on GBM1 and GBM2 maintained in
complete stem medium. Statistical analysis was performed with unpaired
two-tailed t-test (∗p < 0.05, ∗∗p < 0.01;∗∗∗p < 0.001). To confirm that deprivation
of growth factors really increases autophagy, immunoblotting analysis was
performed on cell lysates. LC3-I, LC3-II, and p62 protein levels were assayed
(right panels).
Supplementary Table 1 | Main clinical-pathological features of tumors,
and tumorigenic potential in mice of GBM-derived cell cultures enriched
in CSCs.
Supplementary Table 2 | Inhibition percentage value and statistical
significance of GVS antiproliferative effect on GBM CSCs. Data were
obtained from mean percentage of cell viability of treated cells vs. untreated
control cells for each concentration and time point of GVS exposure. Statistical
analysis was performed with ANOVA test followed by Dunnett’s post-hoc test;
∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 (NS, non-significant; blank boxes, not
performed).
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